Recently, Dongcheng Andico, a wholly-owned subsidiary of Dongcheng Pharmaceutical Group, received the "Drug Registration Certificate" for Technetium [99mTc] Tc Tiludronate Injection issued and approved by the National Medical Products Administration. Technetium [99mTc] Tc tiludronate injection has been granted market approval and can be produced and sold. Technetium [99mTc] Tc tiludronate injection is one of the nuclear medicine products mainly used for SPECT myocardial perfusion imaging in Europe, the United States, and Japan. GE Healthcare has authorized Dongcheng Andico to apply for and hold the drug registration certificate in mainland China, and to produce and distribute the product in the designated area.